inclusion criteria: adults ≥18 years of age history of a respiratory tract infection (rti) for more than one but less than six days including two or more of the following signs and symptoms of an rti: • fever (t ≥ 38.0 c, 100.5 f), cough, sputum production, arthralgia/myalgia, anosmia/ageusia or difficulty breathing. a nasal or throat swab or nasal wash positive by pcr for sars-cov-2. has given written informed consent to participate in the study. due to the public health issues related to this viral infection, witnessed informed consent may be obtained remotely.

inclusion criteria: adults ≥18 years of age history of a respiratory tract infection (rti) for more than one but less than six days including two or more of the following signs and symptoms of an rti: • fever (t ≥ 38.0 c, 100.5 f), cough, sputum production, arthralgia/myalgia, anosmia/ageusia or difficulty breathing. a nasal or throat swab or nasal wash positive by pcr for sars-cov-2. has given written informed consent to participate in the study. due to the public health issues related to this viral infection, witnessed informed consent may be obtained remotely.

inclusion criteria: 1. adults ≥18 years of age 2. history of a respiratory tract infection (rti) for more than one but less than six days including two or more of the following signs and symptoms of an rti: • fever (t ≥ 38.0 c, 100.5 f), cough, sputum production, arthralgia/myalgia, anosmia/ageusia or difficulty breathing. 3. a nasal or throat swab or nasal wash positive by pcr for sars-cov-2. 4. has given written informed consent to participate in the study. due to the public health issues related to this viral infection, witnessed informed consent may be obtained remotely.

inclusion criteria: 1. adults ≥18 years of age 2. history of a respiratory tract infection (rti) for more than one but less than six days including two or more of the following signs and symptoms of an rti: • fever (t ≥ 38.0 c, 100.5 f), cough, sputum production, arthralgia/myalgia, anosmia/ageusia or difficulty breathing. 3. a nasal or throat swab or nasal wash positive by pcr for sars-cov-2. 4. has given written informed consent to participate in the study. due to the public health issues related to this viral infection, witnessed informed consent may be obtained remotely.